COVID-19
Conditions
Keywords
JT001(VV116), Mild to Moderate COVID-19
Brief summary
The purpose of this study is to evaluate the efficacy and safety of JT001 (VV116) Compared With Paxlovid for the Treatment of Coronavirus Disease 2019 (COVID-19) in Participants With Mild to Moderate COVID-19.
Detailed description
Screening Interested participants will sign the appropriate informed consent form (ICF) prior to completion of any study procedures. The investigator will review symptoms, risk factors and other non-invasive inclusion and exclusion criteria prior to any invasive procedures. Treatment and Assessment Period This is the general sequence of events during the 28-day treatment and assessment period: Complete baseline procedures Participants are randomized to an intervention group Participants receive study intervention (Q12H X 5 days), and Complete all safety monitoring
Interventions
Sponsors
Vigonvita Life Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Caregiver, Investigator, Outcomes Assessor)
Intervention model description
Parallel
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participants who have a positive SARS-CoV-2 test result. * Participants who have one or more mild or moderate COVID-19 symptoms, and total symptom score ≥ 2. * Participants who have one or more of the following requirements: ≤7 days from the first positive test for SARS-COV-2 virus infection to the first dose; ≤5 days from the first onset of COVID-19 symptoms to the first dose; SARS-CoV-2 Ct Value ≤20 within 24 hours prior to the first dose. * Participants who satisfy one or more than one of the following high risks for progression to severe COVID-19, including death. * Participants who must agree to adhere to contraception restrictions. * Participants who understand and agree to comply with planned study procedures. * Participants or legally authorized representatives can give written informed consent approved by the Ethical Review Board governing the site. * Capable of giving signed informed consent as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
Exclusion criteria
* Participants who are judged by the investigator as likely to progress to severe/critical COVID-19 prior to randomization. * Participants who have SpO2≤93% on room air at sea level or PaO2/FiO2≤ 300, or respiratory rate ≥30 per minute. * Participants who require mechanical ventilation or anticipated impending need for mechanical ventilation. * Participants who have eye disease. * Participants who have any of the following conditions when screening: ALT or AST\>1.5 ULN; e GFR \<60 mL/min. * Participants who have known allergies to any of the components used in the formulation of the interventions. * Any medical condition, which in the opinion of the Investigator, will compromise the safety of the participant. * Participants who have received a SARS-CoV-2 monoclonal antibody treatment or prevention, or antiviral treatment (including the investigational treatment). * Participants who have received convalescent COVID-19 plasma treatment. * Participant's use of contraindicated drugs in the Package Insert of Nirmatrelvir Tablet/Ritonavir Tablets. * Participants who have participated, within the last 30 days, in a clinical study involving an investigational intervention. If the previous investigational intervention has a long half-life, 5 half-lives or 30 days, whichever is longer, should have passed. * Participants who are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study. * Female who is pregnant or breast-feeding or plan to be pregnant within this study period. * Male whose wife or partner plan to be pregnant within this study period.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time to sustained clinical recovery | Up to 28 days | Time to sustained clinical recovery up to 28 days. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| AEs and SAEs through Day 28 | Up to 28 days | AEs and SAEs through Day 28 |
| Percentage of participants who experience these events by Day 28 | Day 1 to 28 days | Percentage of participants who experience these events by Day 28 Progress to severe and/or critical COVID-19; Death from any cause |
| Percentage of clinical recovery participants | Days 3, 5, 7, 10, 14, 21 and 28 | Percentage of clinical recovery participants from baseline to Days 3, 5, 7, 10, 14, 21 and 28 |
| The change of COVID-19 symptom scores | Days 3, 5, 7, 10, 14, 21 and 28 | The change of COVID-19 symptom scores from baseline to Days 3, 5, 7, 10, 14, 21 and 28, the score ranges from 0 to 33 and higher scores mean a worse symptom. |
| The change of WHO clinical progression scale | Days 3, 5, 7, 10, 14, 21 and 28 | The change of WHO clinical progression scale from baseline to Days 3, 5, 7, 10, 14, 21 and 28, the score ranges from 0 to 10 and higher scores mean a worse clinical progression. |
| Percentage of participants with clinical symptom resolution | Days 3, 5, 7, 10, 14, 21 and 28 | Percentage of participants with clinical symptom resolution from baseline to Days 3, 5, 7, 10, 14, 21 and 28 |
| The change of SARS-COV-2 Ct value | Days 3, 5, 7, 10, 14 | The change of SARS-COV-2 Ct value at Days 3, 5, 7, 10, 14 |
| The change of Chest CT scan | Days 7 or 10 | The change of Chest CT scan from baseline to Days 7 or 10. The change from baseline involves not changed, getting worse, getting better as assessed by the investigator. |
| Percentage of the participants who have progression of COVID-19 though Day 28 | Up to 28 days | Progress to severe and/or critical COVID-19; Death from any cause |
| Percentage of participants whose WHO clinical progression scale reduced at least one level | Days 3, 5, 7, 10, 14, 21 and 28 | Percentage of participants whose WHO clinical progression scale reduced at least one level from baseline to Days 3, 5, 7, 10, 14, 21 and 28. The score ranges from 0 to 10 and the higher scores mean a worse clinical progression level. |
| Time to sustained clinical symptom resolution | Up to 28 days | Time to sustained clinical symptom resolution |
| Percentage of participants with SARS-CoV-2 clearance | Days 3, 5, 7, 10, 14 | Percentage of participants with SARS-CoV-2 clearance on Days 3, 5, 7, 10 and 14 |
Countries
China
Outcome results
None listed